Vertex Pharmaceuticals logo

Vertex Pharmaceuticals(NASDAQ) VRTX

Market Cap$129.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+11,235%
5 Year+185%
1 Year+23%
1 Month-2%
Premium Feature
Moneyball Superscore
89/100
$512.31
+1.80%
+9.06Today
After hours$510.75-$1.56 (-0.31%)
Vertex Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 510.082026-10-09
Vertex Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.06%USD 504.732026-10-02
1 month-2.12%USD 521.122026-09-09
3 month+5.09%USD 485.392026-07-10
Year to date+12.51%USD 453.362025-12-31
1 year+22.95%USD 414.862025-10-09
3 year+41.46%USD 360.572023-10-10
5 year+185.06%USD 178.942021-10-08
Since inception+11,235.11%USD 4.501991-07-24

Vertex Pharmaceuticals Financials at a Glance

Market Cap

$129.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.62B

Net Income (TTM)

$4.41B

EPS (TTM)

$17.19

P/E Ratio

29.68

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$512.31

Volume

1,480,861.861

Open

$502.11

Previous Close

$510.08

Daily Range

$502.06 - $514.90

52-Week Range

$402.58 - $560.25

Estimated Earnings Date

Nov 2, 2026

VRTX News

TMF-Wall-Street-Sign-Purple-StockVStock.png

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Sara AppinoOct 4, 2026
TMF-Wall-Street-Sign-Blue-StockVStock.png

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Sara AppinoOct 1, 2026
GettyImages-research team smiles in lab

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

Adria CiminoSep 29, 2026
Amgen and Vertex Pharmaceuticals logos source-TMF.png

2 Healthcare Stocks That Just Delivered Great News for Investors

Prosper Junior BakinySep 26, 2026
TMF-Wall-Street-Sign-Green-StockVStock.png

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Sara AppinoSep 24, 2026
Vertex Pharmaceuticals logo

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

Prosper Junior BakinySep 18, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsSep 14, 2026
TMF-Pills-Blue-StockVStock.png

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Sara AppinoSep 14, 2026
Page 1

VRTX: Motley Fool Moneyball Superscore

89

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated treats people with life-threatening genetic diseases. These medicines help patients manage cystic fibrosis and blood disorders. The company also develops new ways to treat severe pain.

Medicines for Rare Conditions

  • Cystic Fibrosis Treatments: Therapies like TRIKAFTA and ALYFTREK that treat genetic lung disease; generated $3.2 billion in the second quarter of 2026.
  • Genetic Blood Therapies: CASGEVY uses gene editing to treat sickle cell disease and beta thalassemia; recorded $76.4 million in the second quarter of 2026.
  • Acute Pain Management: JOURNAVX is an approved medicine for moderate-to-severe acute pain; produced $49.6 million in the second quarter of 2026.

Expanding Beyond Cystic Fibrosis

  • Agreed to acquire Crinetics Pharmaceuticals in July 2026 for approximately $10.0 billion to expand into endocrine disease treatments.
  • Acquired Alpine Immune Sciences and its lead molecule, povetacicept, for $5.0 billion in 2024 to target autoimmune diseases.
  • Partnered with Zai Lab and Ono Pharmaceuticals in 2025 to develop and sell povetacicept in Asian markets.
  • Secured reimbursement for ALYFTREK in four additional countries, including Spain, during the second quarter of 2026.

Specialized Science and Global Reach

Vertex operates a specialized global network to manufacture and distribute complex biological and cell therapies. The company maintains a high level of research investment to create first-in-class treatments for diseases with significant unmet needs.

Financial Performance in 2026

  • Total revenues rose to $3.3 billion in the second quarter of 2026, up 12% year over year.
  • Selling, general, and administrative expenses reached $582.2 million in the second quarter of 2026, up 37% year over year.
  • Cash, cash equivalents, and marketable securities totaled $13.6 billion as of June 30, 2026.
  • Market capitalization reached $126.1 billion in the second quarter of 2026, up 10.4% year over year.
  • Research and development expenses totaled $993.8 million in the second quarter of 2026, up 2% year over year.

A Changing Biotechnology Leader

Vertex has evolved from a cystic fibrosis specialist into a multi-disease biotechnology leader. Its expansion into gene editing and pain management diversification strengthens its long-term commercial profile.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,400

CEO

Reshma Kewalramani, MD

Website

www.vrtx.com

Headquarters

Boston, MA 02210, US

VRTX Financials

Key Financial Metrics (TTM)

Gross Margin

86.04%

Operating Margin

38.59%

Net Income Margin

34.89%

Return on Equity

23.31%

Return on Capital

21.11%

Return on Assets

16.06%

Earnings Yield

3.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$129.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

253.46M

Volume

1.48M

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$10.86B

Operating Income

$4.87B

EBITDA

$5.50B

Operating Cash Flow

$4.29B

Capital Expenditure

-$496.80M

Free Cash Flow

$3.80B

Cash & ST Invst.

$7.85B

Total Debt

$1.98B

Vertex Pharmaceuticals Performance Analysis

Vertex Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,748,200,00015.0%
20232023-12-31USD 9,839,000,00012.5%
20242024-12-31USD 10,984,400,00011.6%
20252025-12-31USD 12,074,600,0009.9%
Vertex Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.8%
Q42025-12-314.9%
Q12026-03-31-7.4%
Q22026-06-3011.6%
Vertex Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 12.8242.3%
20232023-12-31USD 13.898.4%
20242024-12-31USD -2.08N/A
20252025-12-31USD 15.32N/A
Vertex Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.3%
Q42025-12-3110.7%
Q12026-03-31-13.5%
Q22026-06-307.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.33B

+12.5%

Gross Profit

$2.84B

+11.2%

Gross Margin

85.33%

N/A

Market Cap

$129.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.20M

N/A

Employees

6,400

N/A

Net Income

$1.10B

+6.5%

EBITDA

$1.45B

+8.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.85B

+23.0%

Total Debt

$1.98B

+29.5%

Accounts Receivable

$2.13B

+12.7%

Inventory

$1.77B

+17.7%

Long Term Debt

$1.98B

+29.5%

Short Term Debt

$0.00

N/A

Return on Assets

16.06%

N/A

Return on Invested Capital

20.74%

N/A

Free Cash Flow

$1.01B

+9.3%

Operating Cash Flow

$1.13B

+4.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALNYAlnylam Pharmaceuticals, Inc.
$232.68+3.63%
BBIOBridgeBio Pharma, Inc.
$65.35+0.48%
BMRNBioMarin Pharmaceutical Inc.
$54.80-0.17%
IONSIonis Pharmaceuticals, Inc.
$45.28+4.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About VRTX

What is the current price of Vertex Pharmaceuticals?

Vertex Pharmaceuticals is trading at $510.08 per share.

What is the 52-week range for Vertex Pharmaceuticals?

Over the past 52 weeks, Vertex Pharmaceuticals has traded between $402.58 and $560.25.

How much debt does Vertex Pharmaceuticals have?

As of the most recent reporting period, Vertex Pharmaceuticals reported total debt of $1.98B.

How much cash does Vertex Pharmaceuticals have on hand?

Vertex Pharmaceuticals reported $6.15B in cash and cash equivalents in its most recent financial results.

What is Vertex Pharmaceuticals’s dividend yield?

Vertex Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services